EVENTS · GILD
PEERS
EARNINGS
Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer. Gilead Sciences Inc. markets established therapies and newer medicines aimed at unmet medical needs, supported by ongoing research and clinical programs across multiple therapeutic areas. The company also works with partnerships and access programs that help expand the reach of its medicines in global markets. Headquartered in Foster City, California, Gilead Sciences Inc. operates as an important healthcare innovator with products and services that serve patients, clinicians, and health systems worldwide.
Drug makers rallied broadly after Amgen and Novo Nordisk both raised their full-year forecasts on strong results, lifting sentiment across the group including Gilead
| Series | 1W | 1M |
|---|---|---|
| GILD | +9.6% | +21.0% |
| Peers | +6.7% | +13.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 80 | 92 |
| QUARTER | EPS EST | EPS ACTUAL | EPS SURPRISE | REACTION |
|---|---|---|---|---|
| Q3 FY2026 | 2.17 | 2.55 | +17.51% | +7.21% |
| Q2 FY2026 | −7.38 | −6.75 | +8.53% | +0.47% |
| Q1 FY2026 | 1.95 | 2.03 | +3.97% | −3.65% |
| Q4 FY2025 | 1.85 | 1.86 | +0.73% | +2.72% |
| Q3 FY2025 | 2.17 | 2.47 | +13.68% | +1.09% |
| PERIOD | EPS EST | REV EST |
|---|---|---|
| Q4 FY2026 | 2.18 | 8.10B |
| FY2026 | −0.42 | 30.70B |
| FY2027 | 9.92 | 32.70B |
| Series | 1W | 1M |
|---|---|---|
| GILD | +9.6% | +21.0% |
| Peers | +6.7% | +13.5% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 80 | 92 |
